Monte Rosa Therapeutics Inc (GLUE) Stock Forecast & Price Target
Monte Rosa Therapeutics Inc · NASDAQ
$14.29+0.45 (+3.25%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Monte Rosa Therapeutics Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $27.00 to $37.00, so the covering firms are broadly aligned. The average target of $29.20 sits 104% above the current $14.29. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.37 next quarter toward $-1.88 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Monte Rosa Therapeutics Inc.
As of Sep, 5 of 5 firms rate GLUE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GLUE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.37
Range $-0.59 – $0.38 · 7 analysts · -33% YoY
Next period, 7 analysts expect Monte Rosa Therapeutics Inc to earn $-0.37 a share (range $-0.59 – $0.38), versus $-0.55 a year earlier. Full-year consensus is $-1.57, growing to $-1.88 the year after.
REVENUE · NEXT QUARTER
$21.6M
Range $0 – $111.0M · 7 analysts · +678% YoY
Revenue is expected to reach $21.6M (range $0 – $111.0M), +677.9% year-over-year. Full-year consensus is $53.7M, rising to $57.1M next year.
Top analysts covering Monte Rosa Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GLUE.
#1
Michael Schmidt
Guggenheim · Rank #2
Buy
$28.00+95.9% to target
Overall win rate
55%
+ Follow
#2
Edward Tenthoff
Piper Sandler · Rank #337
Buy
$37.00+158.9% to target
Overall win rate
29%
+ Follow
#3
Robert Driscoll
Wedbush · Rank #375
Buy
$27.00+88.9% to target
Overall win rate
30%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #390
Buy
$27.00+88.9% to target
Overall win rate
35%
+ Follow
#5
Brian Cheng
JP Morgan
Buy
$27.00+88.9% to target
Coverage
—
+ Follow
GLUE stock forecast FAQ
What is GLUE's average 12-month price target?+
The 5 analysts with a live target average $29.20 for Monte Rosa Therapeutics Inc over the next 12 months, ranging from a $37.00 high to a $27.00 low.
Is GLUE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for GLUE?+
The Street-high target is $37.00 (Piper Sandler), and the Street-low is $27.00 (JP Morgan). The average of all 5 active targets is $29.20.
How many Wall Street analysts cover GLUE?+
5 analysts have an active rating on Monte Rosa Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering GLUE?+
Among analysts who currently cover GLUE, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #2). Their current call is Buy with a $28.00 target.
What is Monte Rosa Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.37 per share (range $-0.59 – $0.38) across 7 analysts. Full-year EPS is projected at $-1.57, rising to $-1.88 the following year.
How much revenue is Monte Rosa Therapeutics Inc expected to report next quarter?+
Consensus revenue is $21.6M (range $0 – $111.0M). Full-year revenue is projected at $53.7M, growing to $57.1M next year.
Have analysts been upgrading or downgrading GLUE lately?+
As of Sep, 5 of 5 firms rate GLUE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GLUE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
